Unfortunately, there will likely be an H3N2 antigenic mismatch with the 2021-2022 Northern Hemisphere influenza vaccine. Our manuscript describing this has been posted on @medrxivpreprint. 1/10 medrxiv.org/content/10.110…
Influenza viruses have circulated at low levels during the COVID-19 pandemic, and population immunity against these viruses is low. As COVID-19-related restrictions are eased or lifted, we expect wide circulation of influenza viruses. 2/10
In recent weeks, a unique H3N2 clade, 3C.2a1b.2a2 (herein 2a2), has circulated at elevated levels in the United States and other parts of the world. 3/10
Viruses within this new clade have several substitutions in key antigenic sites on hemagglutinin (HA) relative to the 2021-2022 Northern Hemisphere H3N2 vaccine strain, a 3C.2a1b.2a1 (herein 2a1) virus. 4/10
We found that one of these substitutions eliminates a key glycosylation site on HA. Although 2a2 viruses have a decrease in receptor specificity breadth, they replicate at least as efficiently as 2a1 H3N2 viruses in both primary and transformed cell culture systems. 5/10
Importantly, we found that antibodies elicited by the 2021-2022 Northern Hemisphere influenza vaccine poorly neutralize the new 2a2 H3N2 clade. 55% of vaccinees had undetectable levels of neutralizing antibodies against 2a2 H3N2 after vaccination. 6/10
Our data provide an antigenic explanation for low VE against 2a2 during a recent outbreak on a college campus. 7/10 cdc.gov/mmwr/volumes/7…
Our study has some limitations. We only measured antibody responses in 40 individuals and most participants in our study were relatively young and healthy. 8/10
It is very important for everyone to receive this year's influenza vaccine. Studies have clearly shown that seasonal influenza vaccines consistently prevent hospitalizations and deaths even in years where there are large antigenic mismatches. 9/10
Influenza vaccinations will be crucial for reducing hospitalizations as SARS-CoV-2 and 2a2 H3N2 viruses co-circulate in the coming months. 10/10
I’m a scientist and I have 2 kids that are between 5 and 11 years old. I respect that some parents have concerns about COVID-19 mRNA vaccines for their young children. Here is a short thread why my wife and I decided to vaccinate both of our kids last week. (1/8)
A lot of my thoughts have been captured by my great colleagues Jeff Gerber and @DrPaulOffit from CHOP in this short editorial published yesterday in Science. Please read this if you haven’t already: (2/8) science.org/doi/10.1126/sc…
As a society, we will eventually need to realize that all of us will be exposed to SARS-CoV-2 sometime during the next few years. The virus will continue to circulate and there is no escaping it unless you do not interact with humans. (3/8)
Check out our new preprint: SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations 1/ medrxiv.org/content/10.110…
We found that both SARS-CoV-2 infections and mRNA vaccinations elicit antibodies that bind to the S1 and S2 regions of the SARS-CoV-2 spike. 2nd doses of vaccine primarily boost antibodies reactive to S1. 2/
Here is where it gets interesting: SARS-CoV-2 infections boost antibodies that react to the S2 region of OC43 (a related seasonal coronavirus). SARS-CoV-2 mRNA vaccines boost OC43-reactive antibodies less than infection. 3/
Our new study evaluating the relationship between common coronavirus antibodies and SARS-CoV-2 susceptibility using a cohort of >2,000 health care workers is now up at @medrxivpreprint. (1/n) medrxiv.org/content/10.110…
We collected serum samples from 2,043 health care workers during the first wave of SARS-CoV-2 activity in Philadelphia, PA. We identified a subset of health care workers who went on to become infected with SARS-CoV-2 after we collected serum samples. (2/n)
Individuals infected during the first wave of SARS-CoV-2 activity in Philadelphia mounted long lived antibody responses and we identified only one potential re-infection event during the second wave. (3/n)
1/ Our paper showing that ~20% of humans possessed non-neutralizing antibodies against SARS-CoV-2 prior to the COVID-19 pandemic was published today @CellCellPress.
There has been recent discussion of how this influenza virus mouse study that I completed as a postdoc potentially relates to current SARS-CoV-2 evolution, so I thought I would write a short thread about it. 1/ @trvrb@LauringLab
Here is the story: influenza viruses do not have a high enough error rate to simultaneously acquire mutations that block all of the different types of antibodies in most polyclonal serum...that part was figured out in 1979 when I was still in diapers....3/
Our new paper showing that some humans possessed non-neutralizing antibodies against SARS-CoV-2 prior to the COVID-19 pandemic is now up at @medrxivpreprint. Importantly, we find that these antibodies are not associated with SARS-CoV-2 protection. 1/7
In our study: 1. We did not find that kids had higher levels of pre-pandemic SARS-CoV-2 cross-reactive antibodies compared to adults. 2. We found that pre-pandemic SARS-CoV-2 cross-reactive antibodies were non-neutralizing. 3/7